

Molecular analysis of the HPJ-JT syndrome and sporadic parathyroid carcinogenesis

Haven, Č.J.

Citation

Haven, C. J. (2008, May 28). *Molecular analysis of the HPJ-JT syndrome and sporadic parathyroid carcinogenesis*. Retrieved from https://hdl.handle.net/1887/12960

Version:	Corrected Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/12960

Note: To cite this publication please use the final published version (if applicable).

Chapter 3

HRPT2, encoding parafibromin, is mutated in hyperparathyroidismjaw tumor syndrome.

Nat. Genet. 2002 Dec;32(4):676-80. Epub 2002 Nov 18.

letter

HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndrome

J.D. Carpten¹, C.M. Robbins¹, A. Villablanca^{2,3}, L. Forsberg^{2,4}, S. Presciuttini⁵, J. Bailey-Wilson⁵,
W.F. Simonds⁶, E.M. Gillanders¹, A.M. Kennedy⁷, J.D. Chen⁸, S.K. Agarwal⁶, R. Sood¹, M.P. Jones¹,
T.Y. Moses¹, C. Haven⁹, D. Petillo⁸, P.D. Leotlela⁷, B. Harding⁷, D. Cameron¹⁰, A.A. Pannett⁷, A. Höög³,
H. Heath III¹¹, L.A. James-Newton⁶, B. Robinson¹², R.J. Zarbo¹³, B.M. Cavaco¹⁴, W. Wassif¹⁵, N.D. Perrier⁶,
I.B. Rosen¹⁶, U. Kristoffersson¹⁷, P.D. Turnpenny¹⁸, L.-O. Farnebo⁴, G.M. Besser¹⁹, C.E. Jackson²⁰,
H. Morreau⁹, J.M. Trent¹, R.V. Thakker⁷, S.J. Marx⁶, B.T. Teh⁸, C. Larsson^{2,8} & M.R. Hobbs²¹

Published online 18 November 2002; doi:10.1038/ng1048

We report here the identification of a gene associated with the hyperparathyroidism-jaw tumor (HPT-JT) syndrome. A single locus associated with HPT-JT (HRPT2) was previously mapped to chromosomal region 1q25-q32. We refined this region to a critical interval of 12 cM by genotyping in 26 affected kindreds. Using a positional candidate approach, we identified thirteen different heterozygous, germline, inactivating mutations in a single gene in fourteen families with HPT-JT. The proposed role of HRPT2 as a tumor suppressor was supported by mutation screening in 48 parathyroid adenomas with cystic features, which identified three somatic inactivating mutations, all located in exon 1. None of these mutations were detected in normal controls, and all were predicted to cause deficient or impaired protein function. HRPT2 is a ubiquitously expressed, evolutionarily conserved gene encoding a predicted protein of 531 amino acids, for which we propose the name parafibromin. Our findings suggest that HRPT2 is a tumor-suppressor gene, the inactivation of which is directly involved in predisposition to HPT-JT and in development of some sporadic parathyroid tumors.

Parathyroid tumors affect 1 in 1,000 individuals in the general population in whom the resulting primary hyperparathyroidism (1°HPT) occurs as the only clinical feature or as part of a complex syndrome. The HPT–JT syndrome (OMIM *145001) is an autosomal dominant, multiple neoplasia syndrome primarily characterized by hyperparathyroidism due to parathyroid tumors^{1,2}. Thirty percent of individuals with HPT–JT may also develop ossifying fibromas, primarily of the mandible and maxilla, which are distinct from the 'brown' tumors associated with severe hyperparathyroidism^{1,3–5}. Kidney lesions may also occur in HPT-JT as bilateral cysts, renal hamartomas or Wilms tumors^{2,5-7}, Linkage analysis previously assigned the locus associated with HPT-JT (*HRPT2*) to a region of roughly 15 cM within 1q24-q32 (refs 5,6,8). Some parathyroid carcinomas and renal hamartomas from individuals with HPT-JT, as well as some sporadic parathyroid adenomas, show somatic 1q loss of heterozygosity (LOH), in agreement with the inactivation of a tumor-suppressor gene in the region^{6,7,9-11}.

To facilitate the identification of the gene associated with HPT-JT, we studied a total of 26 kindreds, sixteen of whom have been described elsewhere and most of whom showed linkage to 1q24-q32 (refs 2,5-7,10,12-16). Twenty-four kindreds were affected with HPT-JT, and two were affected with familial isolated hyperparathyroidism (FIHP). The latter had a familial occurrence only of 1°HPT and showed linkage to 1q24-q32, but not to MEN1. (multiple endocrine neoplasia I; ref. 9). We genotyped 26 microsatellite markers within 1q24-q32. Key recombinants further narrowed the candidate interval to 12 cM flanked by D1S238 and D1S477 (Fig. 1a). Using existing transcript mapping information from this region17 and the UCSC draft human genome sequence browser, we identified 67 potential candidate genes including known genes, full-length cDNAs with no homologies to known genes, spliced expressed sequence tags (ESTs) and predicted genes. Fig. 1b shows a partial transcript map of the critical candidate region highlighting the initial set of candidate genes selected for mutational screening. We carried out mutational analysis using double-stranded DNA sequencing on a panel of 26 lymphocyte DNA samples, each representing one affected individual from each kindred.

nature genetics • volume 32 • december 2002

676

¹Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. ²Department of Molecular Melicine, ³Department of Oncology and Pathology and ⁴Department of Surgical Sciences, Karolinska Hospital, Stockholm, Sweden, ³Inherited Disease Research Branch, National Human Genome Research Institute, Antional Institutes of Health, Baltimore, Maryland, USA. ⁴Melosibil Diseases, Branch, National Institutes and Genome Research Institute, Grand Research Branch, National Human Genome Research Institute, Antional Institutes of Health, Baltimore, Maryland, USA. ⁴Melosibil Diseases, Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, Betheda, Maryland, USA. ⁴Molecular Endocrinology Group, Nuffield Department of Clinical Medicine, University of Oxford, John Raddiffe Hospital, Headington, Oxford, UK. ⁴Laboratory of Cancer Genetics, Van Andel Research, Institute, Grand Rapids, Michigan, USA. ⁵Department of Pathology, Leiden University Medical Center, The Netherlands, ¹⁰Department of Diabetes and Endocrinology, Frincess Alexandra Hospital, Diviersity of Sydney, Australia. ¹¹Di Lilly Company, Lil

After analysis of sequence data from the initial set of prioritized candidate genes, only the C1orf28 gene (Unigene cluster Hs.5722) had probable disease-causing mutations. Unigene cluster Hs.5722 is represented in cDNA libraries from all tissues of interest (parathyroid, kidney and bone), but is probably ubiquitously expressed. The C1orf28 gene consists of 17 exons, all of which are coding (Fig. 1c). Alignment of EST and full-length cDNA sequences from Unigene cluster Hs.5722 identified an open reading frame of 1,596 nucleotides encoding a protein of 531 amino acids. The combined coding sequence data suggested a full-length message of approximately 2.7 kb for this transcript. which correlates well with the major band of roughly 2.7 kb that we detected by northern-blot analysis using the C1orf28 coding region as a probe (Fig. 1d). Other bands present on the northern blot could represent alternative forms of the protein and are currently under investigation. Following the OMIM nomenclature for *145001, we refer to this gene as *HRPT2*. We identified a total of 13 heterozygous germline mutations in

HRPT2 in 14 of the 26 index cases screened (Table 1). Each

germline mutation in HRPT2 is expected to lead to impaired

protein function owing to truncation or premature stops, further

supporting their pathogenetic importance. Inheritance of five different mutations is detailed in Fig. 2. One frameshift mutation, an insertion of 2 bp in exon 7 (Fig. 2d), was found in individuals of two independently identified, seemingly unrelated kindreds (kindred-01 and kindred-33) who were later found to share an identical disease haplotype through the entire 26marker interval, suggesting that these individuals have a common ancestor. In all 14 affected families, all affected and some currently unaffected members of the 14 families harbored mutations. None of the mutations were present in 150 normal diploid control individuals.

HRPT2 and its encoded protein are evolutionarily conserved, as we found potentially orthologous sequences in mouse, Drosophila melanogaster and Caenorhabditis elegans in the National Center for Biotechnology Information non-redundant nucleotide database using the BLAST algorithm. We propose the name parafibromin for the encoded protein, owing to its involvement in the development of parathytroid tumors and ossifying jaw fibromas. Human parafibromin shares 54% identity and 67% similarity with the D. melanogaster ortholog and 25% identity and 45% similarity with the C. elegans ortholog (see Web Fig. A online).




Fig. 1 Genetic analysis of kindreds affected with HPT-IT and partial transcript map of the critical regions. Recombination map spanning 26 microstellite markers from the 1g24-g22 genetic interval showing key recombination events. Marker regions shaded in red regresent regions shared among affected individuals within families. **b**, A partial transcript map of the critical region defined by recombinants. Genes highlighted in blue were initially prioritized for mutational analysis. Clor28 is labeled in red as the gene of interest (*HMPT2*). Known genes and full-length cDNAs are shown with GenBank accession numbers, and ESTs are shown with Unigene cluster ID numbers. Cenomic structure of *HMPT2*. Exes of exons are given in base pairs (bp). ATG and TGA represent the initiation codon and termination codon, respectively, of *HMPT2*. d, Northern-biot analysis using Clor28 (*HRPT2*) as a probe. Clor28 (*HRPT2*) was expressed at varying levels in all tissues examined. Molecular weight markers are given in kb.

nature genetics • volume 32 • december 2002

letter

Kindred or	Clinical data (number)				Mutation in HRPT2			
tumor sample	HPT	PTC	л	KL	Location	Nucleotide change	Coding change	Type
Mutations in kindre	eds affec	ted wit	th HPT	-л				
kindred-05	4	0	2	4	exon 1	3G→A	Met1lleu	germlin
kindred-15	7	0	3	1	exon 1	25C→T	Arg9X	germlin
kindred-16	7	2	5	0	exon 1	41-bp duplication/insertion	frameshift	germlin
kindred-24	2	0	1	1	exon 1	34delAACATCC	frameshift	germlin
kindred-12	4	0	3	0	exon 1	30delG	frameshift	germlin
kindred-19	2	1	2	0	exon 1	39delC	frameshift	germlin
kindred-10	6	1	5	4	exon 2	165C-G	Tyr55X	germlin
kindred-20	7	1	2	1	exon 3	*306delGTgtgagtacttttt	frameshift / splice mutation	germlin
kindred-09	10	3	0	0	exon 4	356delA	frameshift	germlin
kindred-22	3	0	2	1	exon 5	406A→T	Lys136X	germlin
kindred-07	4	0	2	2	exon 7	636delT	frameshift	germlin
kindred-01	5	3	0	3	exon 7	679insAG	frameshift	germlin
kindred-33	2	0	1	0	exon 7	679insAG	frameshift	germlin
kindred-11	3	0	2	1	exon 14	1238delA	frameshift	germlin
Mutations in parati	hyroid tu	mors						
tumor sample 9	sporadic				exon 1	126del24	frameshift / splice mutation	somatio
tumor sample 10	FIHP-1q linked				exon 1	128G→A	Trp43X	somatie
tumor sample 31	sporadic				exon 1	53delT	frameshift	somati

There were no homologies to known protein domains, but moderate identity (32%) and similarity (54%) to a protein of *Saccharomyces cerevisiae* known as Cdc73p, which is an accessory factor associated with an alternative RNA polymerase II important in transcriptional initiation and elongation in yeast^{18–20}.

To evaluate further the probable tumor-suppressor effect of HRPT2, we analyzed LOH and screened for mutations in HRPT2 in tumor and normal DNA from 48 individuals with parathyroid adenomas with cystic features (47 sporadic and 1 familial). Six sporadic tumor samples (12.5%) showed LOH at 1q without involvement of 11q13, two with LOH at 1q encompassing the *HRPT2* locus. We identified a total of three inactivating mutations in *HRPT2*, two in sporadic tumors and one in a tumor from a 1q-linked FIHP kindred. Details on mutations and LOH at 1q for the three tumor samples can be found in Table 1 (also see Web Fig. B online). None of the mutations were detected in adjacent normal tissue or in 150 normal diploid control individuals, suggesting that they were pathogenic for these tumors.

LOH at 1g has been previously reported in tumors from kindreds affected with HPT-JT in whom we identified germline mutations in this study, including kindred-07, kindred-09, kindred-10 and kindred-20, suggesting that biallelic inactivation of HRPT2 is associated with HPT-JT^{6,10,15}. These findings are in agreement with inactivation of a tumor-suppressor gene in the region. But the frequency of demonstrated LOH at 1q in parathyroid tumors related to HPT-JT is relatively low, especially compared with LOH of MEN1, which is inactivated in more than 70% of the associated parathyroid tumors21-23. Our demonstration of a somatic inactivating mutation in a parathyroid adenoma from a kindred affected with FIHP that showed linkage to Ig indicates that small mutations in HRPT2 could be one explanation for the relative lack of LOH at 1g in parathyroid tumors related to HPT-JT. Other possible mechanisms for inactivation of HRPT2 include hypermethylation and regulatory inactivation.

The identification of deleterious disease-associated germline mutations in HRPT2 in 14 kindreds affected with HPT-JT indicates that this gene is directly associated with the pathogenesis of the HPT-JT syndrome. Somatic inactivating mutations in parathyroid tumors suggest an important role for HRPT2 in

parathyroid tumorigenesis. With the identification of HRPT2, the primary gene involved in each of the complex syndromes associated with 1ºHPT is now known24. This finding is expected to be of clinical relevance for early risk assessment in individuals from families with HPT-JT and possibly a subset of individuals with FIHP. As parathyroid tumors are malignant at a higher frequency in HPT-JT than in MEN1 and MEN2, mutations in HRPT2 are probably an important precursor for increased risk of parathyroid carcinoma. Further experimentation is also warranted to determine the actual role of parafibromin in normal cellular function and the exact mechanisms by which abnormal parafibromin leads to the development of tumors. In conclusion, the identification of HRPT2 and further analysis of parafibromin may ultimately contribute to understanding parathyroid tumor development, and eventually to the development of novel therapies for 1°HPT and, possibly, other neoplasms.

Note added in proof: Recent analyses of additional members of kindred 08, an FIHP kindred, has identified a germline L64P mutation in exon 2 of HRPT2.

Methods

Linkage analysis and recombination mapping. All samples used in this study were collected with proper consent and approved for study by institutional review boards and ethics committees at all affiliated institutions. We genotyped genomic DNA samples using 26 short tandem-repeat microsatellite markers in the region of interest of chromosome 1. Primer sequences for the microsatellite repeat markers used in this study are available upon request. PCR reactions were set up using a TECAN Genesis200 robot. PCR amplification was done in 15-µl reactions using GeneAmp 9600 thermocyclers (PE/Applied Biosystems). Depending on the PCR yield, we pooled 5-15 µl of PCR product from up to 12 individual markers of appropriate size and fluorescent label. We separated PCR products using the ABI 377 DNA sequencer (PE/Applied Biosystems), which allows multiple fluorescently-labeled markers to be co-electrophoresed in a single lane. We used the ROX 400 size standard as an internal size-standard in each lane (PE/Applied Biosystems). We calculated allele sizes using the local southern algorithm available in the GENESCAN software program (PE/Applied Biosystems). Allele calling and binning was done using the GENOTYPER software (PE/Applied Biosystems). We included a control individual (CEPH 1347-02) in the genotyping analysis for quality control.

Fig. 2 Mutations in kindreds affected with HPT–JT. Shaded upper left quadrant represents hyperparathyroidism, upper right quadrant rep-resents osifying fibroma of the jaw, lower left quadrant represents renal cysts or other kidney tumors, and lower right quadrant represents parathyroid carcinoma. A line drawn through a symbol represents a deceased individual. Completely open symbols represent individuals who are currently unaffected. Small superscript circles to the upper right of family member symbols rep-resent those individuals for whom DNA was available for mutational analysis. Small superscript circles with an asterisk (*) in the middle represent those individuals who are confirmed mutation carriers. a, Kindred-10 and chromatogram show ing the heterozygous 165C→G nonsense muta tion in exon 2. **b**, Kindred-22 and chromatogram showing the heterozygous 406A→T nonsense mutation in exon 5. **c**, Kindred-07 and chromatograms showing the normal allele and corre-sponding 636delT mutated allele in exon 7. d, Kindred-01 and chromatograms showing the normal allele and corresponding 679insAG mutated allele in exon 7. e, Kindred-11 and chromatograms showing the normal allele and corre-sponding 1238delA mutated allele in exon 14. For c-e, PCR products from single affected individuals carrying mutations were subcloned and subsequently sequenced to obtain sequences for both the mutated and normal alleles from the same individual.


C

e

We created the genetic map of the typed markers using the GAS package version 2.3, applying the genetic model previously used5. We entified critical recombinants by constructing affected haplotypes using Genehunter²⁵, after inspecting the pedigrees to check that the pro-gram had enough information for this task.

PCR amplification and sequencing of germline mutations. We determined the genomic structures for candidate genes and designed primers from intronic sequence flanking coding exons (primer sequences are available upon request). We added M13 tails to all PCR primers for subsequent sequence analysis. We carried out PCR reactions for individual

exons in 50-µl reaction volumes containing 20 ng of genomic DNA, PCR buffer (Invitrogen Life Technologies), 2.25 mM Mg++, 250 nM dNTPs, 10 pmol forward/reverse primer mix, 0.06 unit Platinum Taq DNA poly-merase (Invitrogen Life Technologies) and 0.06 unit AmpliTaq Gold (PE Biosystems). PCR cycles consisted of an initial denaturation at 94 °C for 12 min; 10 cycles of 94 °C for 20 s, annealing for 20 s and 72 °C for 20 s; then 25 cycles of 89 °C for 20 s, annealing for 20 s and 72 °C for 20 s; and a final extension at 72 °C for 10 min. Annealing temperatures were optimized for all primer sets, and this information is available upon request. We analyzed a 5 µl aliquot of PCR product from each reaction on 2% agarose gels to determine robustness of amplification. PCR amplicons were purified using the QiaQuick PCR purification kit on the BioRobot 8000 Automated Nucleic Acid Purification and Liquid Handling system (Qiagen). We carried out double-stranded sequencing using quarter-volume cycle-sequencing reactions prepared in 96-well format using standard M13 forward or reverse primers with the BigDye Terminator Chemistry (PE/Applied Biosystems). After Sephadex purification, we separated sequence products on a 3700 Capillary DNA Analyzer (PE/Applied Biosystems) using manufacturer's protocols. We aligned and analyzed sequence chromatograms using Sequencher version 4.1 (Gene Codes). For PCR products containing potential frameshift mutations, we subcloned PCR products from affected individuals using the TOPO TA cloning system (Invitrogen Life Technologies) according to the manufacturer's recommendations. Positively selected subclones were grown in 3 ml of Luria-Bertani broth supplemented with the appropriate antibiotic selection. We prepared DNA from subclones using the Qiagen Miniprep



Plasmid Purification System. We sequenced plasmid DNA with the standard T7 and M13 reverse primers using BigDye Terminator Chemistry (PE/Applied Biosystems). We separated and analyzed samples as described above.

Northern-blot analysis. To determine the transcript size(s) and tissue distribution pattern of HRPT2, we hybridized PCR products spanning the coding region of the HRPT2 mRNA sequence to a commercially available multiple-tissue northern blot, MTN1 (Clontech). The probes were labeled with α -³²P-dCTP by random priming (Stratagene) following the manufacturer's recommendations. We carried out hybridization at 42 °C overnight in Hybrisol 1 hybridization buffer (Intergen) followed by stringent washing. We then subjected filters to autoradiography.

Detection of mutations in HRPT2 and LOH in tumors. Parathyroid tumors and matched leukocytes were obtained with informed consent in direct connection to surgery at the Karolinska Hospital. Tumor samples 1-9 and 11-48 were from individuals with a sporadic form of the disease and no personal or family history of MEN1, HPT-JT or other familial forms of 1°HPT. Tumor sample 10 was from a member of kindred-06, who was affected with FIHP linked to $1q^9$. Following the procedure and criteria previously described for tumor cases 1–30 (ref. 11), we confirmed that tumor samples 31-48 collected here were cystic parathyroid adenomas. By histopathological examination of representative sections from the frozen tumors, we confirmed that all samples used contained a sufficient proportion of tumor cells for DNA analyses (that is, >70%).

679

letter

all 48 tumors (primers and conditions are available on request). We designed the primers to detect mutations in the coding region as well as at the exon-intron junctions. We carried out cycle-sequencing reactions using the BigDye Terminating cycle sequencing kit (Perkin Elmer). Reactions were separated either using an ABI 377 automated sequencer or a 3700 Capillary DNA Analyzer (PE Applied Biosystems).

We genotyped 48 matched blood and tumor DNA samples using seven microsatellite markers located within the critical region encompassing HRPT2 (Fig. 1). The typed loci included cen-DIS222-DIS461-DIS542-HRPT2-D1S412-D1S2794-D1S2840-D1S2622-tel. In addition, we genotyped tumor samples 31-48 for three microsatellites at the MEN1 locus in 11q13: cen-(D11S4946/MEN1)-D11S493-D11S4937-tel. For tumor samples 1-30, LOH analyses of 11q13 have been previously published¹¹. We analyzed the markers using fluorescence detection, and determined the LOH status both visually and by calculating the peak ratios between the constitutional and tumor alleles.

Accession numbers. Clorf28, AF312865; Cdc73p, NP_013522.

Note: Supplementary information is available on the Nature Genetics website.

Acknowledgments

We gratefully acknowledge the selfless participation of the family members in these studies; the hours of clinical time devoted to these studies by M. Leppert, G. Pidwerny, O.H. Clark, S. Kytölä, E. Korpi-Hyövälti, C.J. Lips, L.E. Mallette, R. van der Luijt, G.J. Fleuren, L. Barros, V. Leite, M.M. Loureiro, M.C. Pereira, L. Ruas, J. Sampson, M.A. Santos, L.G. Sobrinho, A. Hattersley, R. Paisley, M.H. Wheeler, G. Talpos, I. Salti, D. Firat, M.C. Skarulis and N. Thompson; and the expert technical assistance of K. Dietrich, A. Pole, C. Markey, D. F.-Lutz, M.C. Jackson, F. Eddings, G.D. Tran, J. Booth, A.N. Tkachuk and J. Mestre. This work was supported in part by grants from The Swedish Cancer Foundation, the Torsten and Ragnar Söderberg Foundations, the Cornell Foundation and the Gustav V Jubilee Foundation (C.L.), US National Institutes of Health, US National Center for Research Resources Public Health Service Research Grant, the American Cancer Society (M.R.H.), The Dykstra Foundation and the US Public Health Service (C.E.J.), Medical Research Council, U.K. (A.M.K., P.D.L., B.H., A.A.P. and R.V.T.), Rhodes Trust, U.K. (P.D.L.) and Liga Portuguesa Confra o Cancro Instituto Portugues de Oncologia de Francisco Gentil, Portugal (B.M.C.).

Competing interests statement

The authors declare that they have no competing financial interests.

Received 4 September: accepted 24 October 2002

Jackson, C.E. et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 108, 1006–1012; discussion 1012–1013 (1990).

- We screened *HRPT2* for mutations by sequencing the coding region in 2. Wassif, W.S. et al. Genetic studies of a family with hereditary 48 tumore (naimare and conditions are available on respect to Wassif, W.S. et al., Genetic studies of a family with hereditary byperparathyroidism-jaw tumour syndrome. *Clin. Endocrinol.* (0xt) 50, 191–196 hereditary (1999)
 - Kennett, S. & Pollick, H. Jaw lesions in familial hyperparathyroidism. Oral Surg. 4

 - Kennett, S. & Polick, H. Jaw lesions in Tamulai hyperparathytolosm. Ura's Jurg. Toral Med. 2nd Pathol. 31, S02-510 (1971).
 Evenole, L.R., Leider, A.S. & Nelson, K. Ossifying fibroma: a clinicopathologic study of skiry-four cases. Cnd Surg. Cna' Med. Oral Pathol. 60, 505-511 (1985).
 Szabo, J. et al. Hereditary hyperparathytoidism-Jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21–q31. Am. J. Hum. Genet. 56, 944-950 (1995).
 - Genet. 36, 944–950 (1995). Teh, B.T. et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21–q32 and loss of the wild type allele in renal hamartomas. J. Clin. Endocrinol.
 - 1q21-q32 and loss of the wild type allele in renal namartomas. J. Clin. Endocrinol. Metab. 81, 4204-4211 (1996).
 Haven, C.J. et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J. Clin. Endocrinol.
 - Metab. 85, 1449–1454 (2000).
 Hobbs, M.R., Rosen, I.B. & Jackson, C.E. Revised 14.7-CM locus for the hyperparathyroidism–jaw tumor syndrome gene, *HRPT2*. Am. J. Hum. Genet. 70, 1376-1377 (2002).
 - 1376–1377 (2002).
 9. Teh, B. T. et al. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21–q32 in a subset of families. J. Clin. Endocrinol. Metab. 83, 2114–2120 (1998).
 10. Williamson, C. et al. Mapping the gene causing hereditary primary hyperparathyroidism in a Portuguete kindred to chromosome 1q22–q31. J. Bone Minor. Brot. 14, 240–230 (1990).
 - iner. Res. 14, 230-239 (1999).

 - Miner, Res. 14, 230-239 (1999).
 II. Villablanca, A. et al. Genetic and clinical characterization of sporadic cystic parathyroid tumours. *Clin. Endocrinol.* (0xf) 56, 261-269 (2002).
 Iakson, C. E. & Boonstra, C. E. The relationship of hereditary hyperparathyroidism to endocrine adenomatosis. *Am. J. Med.* 43, 727-734 (1967).
 Dinnen, J.S. Greenwood, R.H., Jones, J.H., Walker, D.A. & Williams, E.D. Scharbyroid carcinoma in familial hyperparathyroidism. *J. Clin. Pathol.* 30, 056-071 (1977).
 - Parathyroid carcinoma in ranning representation of the second sec
 - (1999) 15 (1939). Cavaco, B.M. et al. The hyperparathyroidism-jaw tumour syndrome in a Portuguese kindred. Q/M 94, 213–222 (2001).
 - Portuguese kindred. QM/94, 213–222 (2001). IG. Simond, W.E. et al. Familia liolated hyperparathyroldism: clinical and genetic characteristics of 36 kindreds. *Medicine (Baltimore)* 81, 1–26 (2002). 17, Sood, R. et al. Cloning and characterization of 13 novel transcripts and the human RGSS gene from the 1q25 region encompassing the hereditary prostate
 - ancer (HPC1) locus. Genomics 73, 211-222 (2001).
 - canter (virv. 1) IOLIS. Genomics 78, 211–222 (2001).
 18. Shi, X. et al. Cdc73p and Paf1p are found in a novel RNA polymerase li-containing complex distinct from the Srbp-containing holoenzyme. *Mol. Cell Biol.* 17, 1160–1169 (1997).
 - Control (1997).
 Kerkmann, K. & Lehming, N. Genome-wide expression analysis of a Saccharomyces cerevisiae strain deleted for the Tup1p-interacting protein Cdr/3p. Curr Genet. 39, 284–290 (2001).
 Pokholok, D.K., Hannett, N.M. & Young, R.A. Exchange of RNA polymerase II initiation and elongation factors during gene expression in vivo. Mol. Cell 9, 759–809 (2002).

 - Thakker, R.V. et al. Association of parathyroid tumors in multiple endocrin 21 Thakes, N.Y. et al. Association of paratryload utility in mituble endotrine neoplaisi type 1 with loss of alleles on chromosome 11. N. Engl. J. Med. 321, 218-224 (1989).
 Bystrom, C. et al. Localization of the MENT gene to a small region within
 - me 11q13 by deletion mapping in tumors. Proc. Natl Acad. Sci. USA 87, 1968-1972 (1990)
 - Friedman, E. et al. Allelic loss from chromosome 11 in parathyroid tumors. Cancer Res. 52, 6804–6809 (1992). 23

 - Net: 54, 6904–8909 (1992).
 24. Marx, S.J. Nyperparatityroid and hypoparathyroid disorders. N. Engl. J. Med. 343, 1863–1875 (2000).
 25. Kruplyak, L., Daly, M.J., Reeve-Daly, M.P. & Lander, E.S. Parametric and nonparametric linkage analysis: a unified multipoint approach. Am. J. Hum. Genet. 58, 1347–1353 (1996).